The role of ¹⁸F-FDG PET/CT in evaluation of therapy effectiveness and prognosis of lymphomas

 Aim. To determine the diagnostic value of positron emission tomography (PET)/computed tomography (CT) with F-18 fluorodeoxyglucose (18F-FDG) for monitoring the effectiveness and prognosis of lymphoma therapy.

Materials and methods. Retrospective data of 18F-FDG PET/CT (before treatment (PET1), after two cycles (PET2), and after completion of chemotherapy (PET3)) in 30 people with lymphomas were analyzed.

Results. A complete metabolic response in PET2 (PET2–) was observed in 21 patients (70%). In 9 patients in PET2–, a partial metabolic response (6 people), lack of metabolic response (2 people), or metabolic progression (1
person) were detected. These patients comprised the PET2+ group.
After chemotherapy, a complete metabolic response (PET3–) was diagnosed in 26 patients (87%). This effect was achieved in 21 patients (100%) with PET2– and in 5 patients (66%) with PET2+. Of the 9 patients in the PET2+ group, in 4 (44%) patients, a partial metabolic response or no metabolic response was diagnosed. Further monitoring of these patients showed that progression was diagnosed in 2 cases, and in 2 patients, further treatment resulted in complete remission. A two-year follow-up of patients revealed that remission was observed in 20 (67%) patients. The analysis of the results of PET2 showed that a relapse of the disease was observed in 6 (67%) PET2+ patients and remission was noted in 3 (33%) patients. In PET2– patients, a relapse was diagnosed in 4 (19%) persons, and remission was established in 17 (81%) patients.

Conclusion. Early PET/CT with 18F-FDG allows to predict the effect of  lymphoma treatment. The method can be recommended for monitoring lymphoma therapy. 

1. Каприн А.Д., Старинский В.В., Петрова Г.В. Злокачественные новообразования в России в 2016 году (заболеваемость и смертность). М.: МНИОИ им. П.А. Герцена, филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2018: 250.

2. Рукавицин О.А. Гематология: национальное руководство. М.: ГЭОТАР-Медиа, 2015: 776.

3. Zucca E., Copie-Bergman C., Ricardi U., Thieblemont C., Raderer M., Ladetto M. Gastric marginal zone lymphoma of MALT type: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 2013; 24: 144–148. DOI: 10.1093/annonc/mdt343.

4. Чернов В.И., Дудникова Е.А., Гольдберг В.Е., Кравчук Т.Л., Данилова А.В., Зельчан Р.В., Медведева А.А., Синилкин И.Г., Брагина О.Д., Попова Н.О., Гольдберг А.В. Позитронная эмиссионная томография в диагностике и мониторинге лимфопролиферативных заболеваний. Медицинская радиология и радиационная безопасность. 2018; 63 (6): 41–50. DOI: 10.12737/article_5c0b8d72a8bb98.40545646.

5. Чанчикова Н.Г., Дудникова Е.А., Карлова Е.А., Савельева А.С., Силкина О.А., Зельчан Р.В., Синилкин И.Г., Брагина О.Д., Медведева А.А., Чернов В.И. Возможности ПЭТ/КТ с 18F-ФДГ в диагностике и стадировании лимфом. Вопросы онкологии. 2019; 65 (1): 147–153. DOI: 10.37469/0507-3758-2019-65-1-147-153.

6. Chernov V.I., Dudnikova E.A., Zelchan R.V., Kravchuk T.L., Danilova A.V., Medvedeva A.A., Sinilkin I.G., Bragina O.D., Goldberg V.E., Goldberg A.V., Frolova I.G. The first experience of using 99mTc-1-thio- d-glucose for single-photon emission computed tomography imaging of lymphomas. Siberian Journal of Oncology. 2018; 17 (4): 81–87. DOI: 10.21294/1814-4861-2018-17-4-81-87.

7. Чернов В.И., Дудникова Е.А., Гольдберг В.Е., Кравчук Т.Л., Данилова А.В., Зельчан Р.В., Медведева А.А., Синилкин И.Г., Брагина О.Д., Белевич Ю.В., Королева Е.С. Однофотонная эмиссионная компьютерная томография в диагностике и мониторинге лимфопролиферативных заболеваний. Медицинская радиология и радиационная безопасность. 2019; 64 (3): 58–63. DOI: 10.12737/article_5cf3dfefe60b13.90120976.

8. Zelchan R., Chernov V., Medvedeva A., Sinilkin I., Stasyuk E., Rogov A., Il’ina E., Skuridin V., Bragina O. Study of a glucose derivative labeled with technetium-99m as potential radiopharmaceutical for cancer diagnosis EP634. Eur. J. Nucl. Med. Mol. Imaging. 2016; 43 (1): S466.

9. Sasaki M., Kuwabara Y., Koga H., Nakagawa M., Chen T., Kaneko K., Havashi K., Nakamura K., Masuda K. Clinical impact of whole body FDG-PET on the staging and therapeutic decision making for malignant lymphoma. Annals of Nuclear Medicine. 2002; 16 (5): 337–345. DOI: 10.1007/BF02988618.

10. Поддубная И.В., Савченко В.Г. Российские клинические рекомендации по диагностике и лечению лимфопролиферативных заболеваний. М.: МедиаМедика, 2013: 104.

11. Cheson B.D., Fisher R.I., Barrington S.F., Cavalli F., Schwartz L.H., Zucca E., Lister T.F. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. Journal of Clinical Oncology. 2014; 32 (27): 3059–3068. DOI: 10.1200/JCO.2013.54.8800.

12. Romer W., Hanauske A.R., Ziegler S., Thodtmann R., Weber W., Fuchs C., Enne W., Herz M., Nerl C., Garbrecht M., Schwaiger M. Positron emission tomography in non-Hodgkin’s lymphoma: assessment of chemotherapy with fluorodeoxyglucose. Blood. 1998; 91 (12): 4464–4471.

13. Radford J., Illidge T., Counsell N., Hancock B., Pettengell R., Johnson P., Wimperis J., Culligan D., Popova B., Smith P., McMillan A., Brownell A., Kruger A., Lister A., Hoskin P., O’Doherty M., Barrington S. Results of a Trial of PET-Directed Therapy for Early- Stage Hodgkin’s Lymphoma. New England Journal of Medicine. 2015; 372 (17): 1598–1607. DOI: 10.1056/NEJMoa1408648.

14. Kostakoglu L., Cheson B.D. State-of-the-art research on “Lymphomas: Role of molecular imaging for staging, prognostic evaluation, and treatment response”. Front. Oncol. 2013; 3: 212. DOI: 10.3389/fonc.2013.00212.

15. Dreyling M., Ghielmini M., Marcus R., Salles G., Vitolo U., Ladetto M., ESMO Guidelines Working Group. Newly diagnosed and relapsed follicular lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 2014; 25 (3): 76–82. DOI: 10.1093/annonc/mdu200.

16. Gallamini A., Barrington S.F., Biggi A., Chauvie S., Kostakoglu L., Gregianin M., Meignan M., Mikhaeel G.N., Loft A., Zaucha J.M., Seymour J.F., Hofman M.S., Rigacci L., Pulsoni A., Coleman M., Dann E.J., Trentin L., Casasnovas O., Rusconi C., Brice P., Bolis S., Viviani S., Salvi F., Luminari S., Hutchings M. The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville fivepoint scale. Haematologica. 2014; 99 (6): 1107–1113. DOI: 10.3324/haematol.2013.103218.

17. Biggi A., Gallamini A., Chauvie S., Hutchings M., Kostakoglu L., Gregianin M., Meignan M., Malkowski B., Hofman M.S., Barrington S.F. International validation study for interim PET in ABVD-treated, advanced-stage hodgkin lymphoma: interpretation criteria and concordance rate among reviewers. J. Nucl. Med. 2013; 54 (5): 683–690. DOI: 10.2967/jnumed.112.110890.

18. Markova J., Kahraman D., Kobe C., Skopalova M., Mocikova H., Klaskova K., Dedeckova K., Eich H., Böll B., Dietlein M., Kozak T. Role of [18F]-fluoro-2-deoxy-D-glucose positron emission tomography in early and late therapy assessment of patients with advanced Hodgkin lymphoma treated with bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine and prednisone. Leuk. Lymphoma. 2012; 53 (1): 64–70. DOI: 10.3109/10428194.2011.603444.